NUVL News and Press, Nuvalent Inc. From 12/13/22

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 PR Newswire Publication provides comprehensive assessment of NVL-520's activity spanning preclinical characterization and preliminary clinical case stud...

Summary Two new Breakout Stocks for Week 50 with better than 10% short-term upside potential and one Dow 30 Pick. Average cumulative returns now up to +131.5% YTD. This week 1 of 4 high frequency breakout picks gained over 10% in less than a week with peak gains in VITL +10.4% while PBT...

Summary Two new Breakout Stocks for Week 46 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now up to +116.9% YTD. This week two picks gained 10% in less than a week with MAG +14.9% and CLNE +15.4% for total portfolio gains over 5%. ...

Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results PR Newswire Preliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-class potential of NVL-520 for patient...

Summary Two new Breakout Stocks for Week 45 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +109.9% YTD. This week one stock gained 10% in less than a week with EPM +10.6% and GWH +7.6% while ENVX missed Q3 earnings for a ...

Nuvalent Announces Closing of Upsized Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass. , Nov. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapie...

Nuvalent Announces Pricing of Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass. , Oct. 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for c...

Nuvalent ( NASDAQ: NUVL ) shares fell over 6% Monday morning after the biopharmaceutical company launched an underwritten public offering of $200M of its shares of Class A common stock. All shares are being offered by Nuvalent ( NUVL ). In addition, Nuvalent ( ...

Nuvalent Announces Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass. , Oct. 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinica...

Summary Two new Breakout Stocks for Week 44 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now up to +112.8% YTD. This week two stocks gained 10% in less than a week with MAG +11.5% and WTTR +10% while another high frequency breakout...